162 related articles for article (PubMed ID: 11180195)
1. Effect of ionization on the variable uptake of valacyclovir via the human intestinal peptide transporter (hPepT1) in CHO cells.
Balimane P; Sinko P
Biopharm Drug Dispos; 2000 Jul; 21(5):165-74. PubMed ID: 11180195
[TBL] [Abstract][Full Text] [Related]
2. Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line.
Guo A; Hu P; Balimane PV; Leibach FH; Sinko PJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):448-54. PubMed ID: 10087037
[TBL] [Abstract][Full Text] [Related]
3. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir.
Balimane PV; Tamai I; Guo A; Nakanishi T; Kitada H; Leibach FH; Tsuji A; Sinko PJ
Biochem Biophys Res Commun; 1998 Sep; 250(2):246-51. PubMed ID: 9753615
[TBL] [Abstract][Full Text] [Related]
4. Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter.
Han HK; Oh DM; Amidon GL
Pharm Res; 1998 Sep; 15(9):1382-6. PubMed ID: 9755889
[TBL] [Abstract][Full Text] [Related]
5. Carrier-mediated intestinal absorption of valacyclovir, the L-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats.
Sinko PJ; Balimane PV
Biopharm Drug Dispos; 1998 May; 19(4):209-17. PubMed ID: 9604120
[TBL] [Abstract][Full Text] [Related]
6. Delineation of human peptide transporter 1 (hPepT1)-mediated uptake and transport of substrates with varying transporter affinities utilizing stably transfected hPepT1/Madin-Darby canine kidney clones and Caco-2 cells.
Bhardwaj RK; Herrera-Ruiz D; Sinko PJ; Gudmundsson OS; Knipp G
J Pharmacol Exp Ther; 2005 Sep; 314(3):1093-100. PubMed ID: 15901802
[TBL] [Abstract][Full Text] [Related]
7. 5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter.
Han H; de Vrueh RL; Rhie JK; Covitz KM; Smith PL; Lee CP; Oh DM; Sadée W; Amidon GL
Pharm Res; 1998 Aug; 15(8):1154-9. PubMed ID: 9706043
[TBL] [Abstract][Full Text] [Related]
8. Intra- and interindividual variabilities of valacyclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor.
Phan DD; Chin-Hong P; Lin ET; Anderle P; Sadee W; Guglielmo BJ
Antimicrob Agents Chemother; 2003 Jul; 47(7):2351-3. PubMed ID: 12821497
[TBL] [Abstract][Full Text] [Related]
9. Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2.
Ganapathy ME; Huang W; Wang H; Ganapathy V; Leibach FH
Biochem Biophys Res Commun; 1998 May; 246(2):470-5. PubMed ID: 9610386
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of analogs of L-valacyclovir and determination of their substrate activity for the oligopeptide transporter in Caco-2 cells.
Friedrichsen GM; Chen W; Begtrup M; Lee CP; Smith PL; Borchardt RT
Eur J Pharm Sci; 2002 Jul; 16(1-2):1-13. PubMed ID: 12113886
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism.
Anand BS; Katragadda S; Mitra AK
J Pharmacol Exp Ther; 2004 Nov; 311(2):659-67. PubMed ID: 15226381
[TBL] [Abstract][Full Text] [Related]
12. CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs.
Han HK; Rhie JK; Oh DM; Saito G; Hsu CP; Stewart BH; Amidon GL
J Pharm Sci; 1999 Mar; 88(3):347-50. PubMed ID: 10052994
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of corneal permeation of L-valyl ester of acyclovir: targeting the oligopeptide transporter on the rabbit cornea.
Anand BS; Mitra AK
Pharm Res; 2002 Aug; 19(8):1194-202. PubMed ID: 12240946
[TBL] [Abstract][Full Text] [Related]
14. Drug inhibition of Gly-Sar uptake and hPepT1 localization using hPepT1-GFP fusion protein.
Sun D; Landowski CP; Chu X; Wallsten R; Komorowski TE; Fleisher D; Amidon GL
AAPS PharmSci; 2001; 3(1):E2. PubMed ID: 11741253
[TBL] [Abstract][Full Text] [Related]
15. Interactions of the dipeptide ester prodrugs of acyclovir with the intestinal oligopeptide transporter: competitive inhibition of glycylsarcosine transport in human intestinal cell line-Caco-2.
Anand BS; Patel J; Mitra AK
J Pharmacol Exp Ther; 2003 Feb; 304(2):781-91. PubMed ID: 12538834
[TBL] [Abstract][Full Text] [Related]
16. Dipeptide model prodrugs for the intestinal oligopeptide transporter. Affinity for and transport via hPepT1 in the human intestinal Caco-2 cell line.
Nielsen CU; Andersen R; Brodin B; Frokjaer S; Taub ME; Steffansen B
J Control Release; 2001 Sep; 76(1-2):129-38. PubMed ID: 11532319
[TBL] [Abstract][Full Text] [Related]
17. Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice.
Yang B; Smith DE
Drug Metab Dispos; 2013 Mar; 41(3):608-14. PubMed ID: 23264448
[TBL] [Abstract][Full Text] [Related]
18. A physiologically based pharmacokinetic model for valacyclovir established based on absolute expression quantity of hPEPT1 and its application.
Sun L; Wang C; Zhang Y
Eur J Pharm Sci; 2018 Oct; 123():560-568. PubMed ID: 30081070
[TBL] [Abstract][Full Text] [Related]
19. Human dipeptide transporter, hPEPT1, stably transfected into Chinese hamster ovary cells.
Covitz KM; Amidon GL; Sadée W
Pharm Res; 1996 Nov; 13(11):1631-4. PubMed ID: 8956326
[TBL] [Abstract][Full Text] [Related]
20. The extracellular pH dependency of transport activity by human oligopeptide transporter 1 (hPEPT1) expressed stably in Chinese hamster ovary (CHO) cells: a reason for the bell-shaped activity versus pH.
Fujisawa Y; Tateoka R; Nara T; Kamo N; Taira T; Miyauchi S
Biol Pharm Bull; 2006 May; 29(5):997-1005. PubMed ID: 16651734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
